Skip to main content
. 2017 Aug 30;12(8):e0182885. doi: 10.1371/journal.pone.0182885

Fig 2. Median PFS in OS axis for sequential treatments in T790M positive and negative advanced NSCLC patients.

Fig 2

Survival outcome of afatinib treatment is shown after first generation EGFR-TKI treatment. The X-axis represents the overall survival. The bars indicate the progression free survival for afatinib.